Profiel
Jason Chin is the founder of Constructive Bio Ltd.
He is currently working as an Independent Non-Executive Director at Genus Plc.
Actieve functies van Jason Chin
Bedrijven | Functie | Begin |
---|---|---|
GENUS PLC | Director/Board Member | 01-04-2021 |
Constructive Bio Ltd.
Constructive Bio Ltd. BiotechnologyHealth Technology Constructive Bio Ltd. is a British biotechnology company that rewrites genomes to create biomolecules that were previously unimaginable. The company is based in Cambridge, UK and is backed by a world-class syndicate of investors including Ahren Innovation Capital, Amadeus Capital Partners, OMX Ventures, and General Inception. The company is creating next-generation therapeutics and industrial solutions while setting the standard for genetic code reprogramming. With a world-class team in synthetic genomics and a passionate commitment to improving health and bioprocessing, Constructive Bio is reimagining the world of biologic therapies by rewriting the genome itself. | Founder | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
GENUS PLC | Process Industries |
Bedrijven in privébezit | 1 |
---|---|
Constructive Bio Ltd.
Constructive Bio Ltd. BiotechnologyHealth Technology Constructive Bio Ltd. is a British biotechnology company that rewrites genomes to create biomolecules that were previously unimaginable. The company is based in Cambridge, UK and is backed by a world-class syndicate of investors including Ahren Innovation Capital, Amadeus Capital Partners, OMX Ventures, and General Inception. The company is creating next-generation therapeutics and industrial solutions while setting the standard for genetic code reprogramming. With a world-class team in synthetic genomics and a passionate commitment to improving health and bioprocessing, Constructive Bio is reimagining the world of biologic therapies by rewriting the genome itself. | Health Technology |